{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:48:51Z","timestamp":1787730531387,"version":"build-2784847793"},"reference-count":137,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semradonc.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:28:07Z","timestamp":1757514487000},"page":"495-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Contemporary Advances, Evidence, and Considerations in Preoperative Therapy for Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Alexander D.","family":"Sherry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra K.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Truty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7590-558X","authenticated-orcid":false,"given":"Krishan R.","family":"Jethwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0001","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.semradonc.2025.07.007_bib0002","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1245\/s10434-024-15443-1","article-title":"Radiologic occult metastases in pancreatic cancer: analysis of risk factors and survival outcomes in the age of contemporary neoadjuvant multiagent chemotherapy","volume":"31","author":"Yee","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.007_bib0003","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/COC.0000000000001076","article-title":"Executive summary of the American Radium Society Appropriate use criteria for neoadjuvant therapy for nonmetastatic pancreatic adenocarcinoma: systematic review and guidelines","volume":"47","author":"Jethwa","year":"2024","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0004","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2014.05.030","article-title":"Clinical usefulness of 18F-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent chemoradiation therapy","volume":"90","author":"Chang","year":"2014","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0005","series-title":"Pancreatic Cancer: a Multidisciplinary Approach","first-page":"67","article-title":"Diagnosis and staging of pancreatic cancer: laparoscopy","author":"Donovan","year":"2022"},{"issue":"25","key":"10.1016\/j.semradonc.2025.07.007_bib0006","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1200\/JCO.20.00996","article-title":"Time to reconsider staging laparoscopy in pancreatic cancer?","volume":"38","author":"Peters","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0007","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/XCS.0000000000000704","article-title":"Yield of staging laparoscopy for pancreatic cancer in the modern era: analysis of more than 1,000 consecutive patients","volume":"237","author":"Gudmundsdottir","year":"2023","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0008","article-title":"Outcomes of visceral arterial interposition graft reconstruction for locally advanced pancreatic cancer","author":"Yonkus","year":"2024","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0009","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1148\/radiol.13131184","article-title":"Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association","volume":"270","author":"Al-Hawary","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0010","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Cancer V.2.2025. 2025. Accessed April 13, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"issue":"9","key":"10.1016\/j.semradonc.2025.07.007_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092584","article-title":"Current approaches for the curative-intent surgical treatment of pancreatic ductal adenocarcinoma","volume":"15","author":"S\u0142odkowski","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.semradonc.2025.07.007_bib0013","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1245\/s10434-016-5715-0","article-title":"Modified frailty index predicts morbidity and mortality after pancreaticoduodenectomy","volume":"24","author":"Mogal","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.07.007_bib0014","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/j.prro.2022.06.004","article-title":"Patterns of recurrence after primary local therapy for pancreatic ductal adenocarcinoma: A critical review of rationale and target delineation for (Neo)adjuvant radiation therapy","volume":"12","author":"Jethwa","year":"2022","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.07.007_bib0015","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ijrobp.2010.04.058","article-title":"Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning","volume":"80","author":"Arvold","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0016","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijrobp.2012.11.019","article-title":"Tumor size on abdominal MRI versus pathologic specimen in resected pancreatic adenocarcinoma: implications for radiation treatment planning","volume":"86","author":"Hall","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.007_bib0017","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2012.07.004","article-title":"Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning","volume":"104","author":"Qiu","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0018","doi-asserted-by":"crossref","unstructured":"Chuong M.D., Ashman J., Jethwa K., et al. Moving from the background towards the spotlight: a critical review of radiation therapy for locally advanced pancreas cancer. Int J Radiat Oncol*Biol*Phys;doi:https:\/\/doi.org\/10.1016\/j.ijrobp.2025.02.022","DOI":"10.1016\/j.ijrobp.2025.02.022"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.007_bib0019","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MPA.0b013e31818166e6","article-title":"Nerve plexus invasion in pancreatic cancer: spread patterns on histopathologic and embryological analyses","volume":"37","author":"Makino","year":"2008","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.007_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4329\/wjr.v4.i2.36","article-title":"CT and MR imaging patterns for pancreatic carcinoma invading the extrapancreatic neural plexus (Part I): anatomy, imaging of the extrapancreatic nerve","volume":"4","author":"Zuo","year":"2012","journal-title":"World J Radiol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.07.007_bib0021","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/RCT.0b013e3181dd5bfc","article-title":"Arterial anatomy of the pancreas. Part 3: segmented computed tomography-angiography mapping of perineural invasion","volume":"34","author":"Collins","year":"2010","journal-title":"J Comput Assist Tomogr"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.007_bib0022","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00006676-200310000-00005","article-title":"Innervation of the pancreas from the perspective of perineural invasion of pancreatic cancer","volume":"27","author":"Yi","year":"2003","journal-title":"Pancreas"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.007_bib0023","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.semradonc.2025.07.007_bib0024","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"issue":"29","key":"10.1016\/j.semradonc.2025.07.007_bib0025","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1200\/JCO.2010.30.3446","article-title":"Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012\/FFCD-9203\/GERCOR phase II study","volume":"28","author":"Van Laethem","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.007_bib0026","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"Jama"},{"issue":"10073","key":"10.1016\/j.semradonc.2025.07.007_bib0027","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.semradonc.2025.07.007_bib0028","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semradonc.2025.07.007_bib0029","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","article-title":"Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group","volume":"230","author":"Klinkenbijl","year":"1999","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.semradonc.2025.07.007_bib0030","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.007_bib0031","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006676-200404000-00002","article-title":"Pancreatic Cancer Registry in Japan: 20 years of experience","volume":"28","author":"Matsuno","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0032","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1748-717X-5-28","article-title":"Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence","volume":"5","author":"Sun","year":"2010","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.007_bib0033","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.gassur.2005.09.016","article-title":"Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings","volume":"10","author":"Hishinuma","year":"2006","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"10.1016\/j.semradonc.2025.07.007_bib0034","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/SLA.0b013e318156eef3","article-title":"Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891","volume":"246","author":"Smeenk","year":"2007","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.semradonc.2025.07.007_bib0035","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/1097-0142(19931001)72:7<2118::AID-CNCR2820720710>3.0.CO;2-4","article-title":"An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging","volume":"72","author":"Kayahara","year":"1993","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2025.07.007_bib0036","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ijrobp.2013.09.005","article-title":"Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design","volume":"87","author":"Dholakia","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0037","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13014-016-0714-7","article-title":"Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial location","volume":"11","author":"Yu","year":"2016","journal-title":"Radiat Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.007_bib0038","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs Gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.007_bib0039","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","article-title":"Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized Adjuvant chemotherapy trial","volume":"154","author":"Jones","year":"2019","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.007_bib0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annonc.2020.11.013","article-title":"Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine","volume":"32","author":"Casolino","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.007_bib0041","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/SLA.0000000000002925","article-title":"Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective CLUSTER study","volume":"268","author":"Gemenetzis","year":"2018","journal-title":"Ann Surg"},{"issue":"10073","key":"10.1016\/j.semradonc.2025.07.007_bib0042","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.007_bib0043","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"Adjuvant nab-Paclitaxel + Gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial","volume":"41","author":"Tempero","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.semradonc.2025.07.007_bib0044","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.19.00946","article-title":"Potentially curable pancreatic adenocarcinoma: ASCO clinical practice Guideline update","volume":"37","author":"Khorana","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2025.07.007_bib0045","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archsurg.1985.01390320023003","article-title":"Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection","volume":"120","author":"Kaiser","year":"1985","journal-title":"Arch Surg"},{"issue":"12","key":"10.1016\/j.semradonc.2025.07.007_bib0046","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.007_bib0047","first-page":"436","article-title":"Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new","volume":"6","author":"Boyle","year":"2015","journal-title":"J Gastrointest Oncol"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.07.007_bib0048","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2024.42.16_suppl.4005","article-title":"NRG Oncology\/RTOG 0848: results after adjuvant chemotherapy \u00b1 chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA)","volume":"42","author":"Abrams","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2025.07.007_bib0049","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1245\/s10434-021-10075-1","article-title":"The Landmark Series: preoperative therapy for pancreatic cancer","volume":"28","author":"Patel","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.07.007_bib0050","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.pan.2020.07.411","article-title":"Prehabilitation prior to surgery for pancreatic cancer: a systematic review","volume":"20","author":"Bundred","year":"2020","journal-title":"Pancreatology"},{"issue":"10","key":"10.1016\/j.semradonc.2025.07.007_bib0051","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.semradonc.2025.07.007_bib0052","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Pv","year":"2012","journal-title":"New Engl J Med"},{"issue":"16","key":"10.1016\/j.semradonc.2025.07.007_bib0053","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1002\/cncr.34273","article-title":"Preoperative therapy for pancreatic adenocarcinoma-precision beyond anatomy","volume":"128","author":"Seo","year":"2022","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.007_bib0054","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1245\/s10434-021-10991-2","article-title":"Neoadjuvant chemotherapy switch in borderline resectable\/locally advanced pancreatic cancer","volume":"29","author":"Alva-Ruiz","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.007_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0056","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.007_bib0057","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0058","first-page":"15","article-title":"Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: a national cancer database analysis","volume":"27","author":"Miccio","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0059","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"issue":"23","key":"10.1016\/j.semradonc.2025.07.007_bib0060","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1002\/cncr.27636","article-title":"Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators","volume":"118","author":"Katz","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0061","doi-asserted-by":"crossref","unstructured":"van Kooten R.T., Bahadoer R.R., Peeters K.C.M.J., et al. Preoperative risk factors for major postoperative complications after complex gastrointestinal cancer surgery: a systematic review. Eur J Surg Oncol. 47(12):3049-3058. doi:https:\/\/doi.org\/10.1016\/j.ejso.2021.07.021","DOI":"10.1016\/j.ejso.2021.07.021"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.007_bib0062","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","article-title":"Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer","volume":"260","author":"Merkow","year":"2014","journal-title":"Ann Surg"},{"issue":"34","key":"10.1016\/j.semradonc.2025.07.007_bib0063","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.21.01220","article-title":"Value of neoadjuvant radiation therapy in the management of pancreatic adenocarcinoma","volume":"39","author":"Hall","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0064","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","article-title":"Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial","volume":"191","author":"Golcher","year":"2015","journal-title":"Strahlenther Onkol"},{"issue":"10","key":"10.1016\/j.semradonc.2025.07.007_bib0065","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","article-title":"Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets","volume":"19","author":"Casadei","year":"2015","journal-title":"J Gastrointest Surg"},{"issue":"16","key":"10.1016\/j.semradonc.2025.07.007_bib0066","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.semradonc.2025.07.007_bib0067","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"Cmaj"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.007_bib0068","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.3379","article-title":"Differential treatment effects of subgroup analyses in phase 3 oncology trials from 2004 to 2020","volume":"7","author":"Sherry","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4_suppl","key":"10.1016\/j.semradonc.2025.07.007_bib0069","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.2019.37.4_suppl.189","article-title":"Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP-05)","volume":"37","author":"Unno","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.007_bib0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/sim.7901","article-title":"Randomization: the forgotten component of the randomized clinical trial","volume":"38","author":"Rosenberger","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111540","article-title":"A meta-epidemiological analysis of post-hoc comparisons and primary endpoint interpretability among randomized noncomparative trials in clinical medicine","volume":"175","author":"Sherry","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0073","doi-asserted-by":"crossref","unstructured":"Seufferlein T., Uhl W., Kornmann M., et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX): a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. ;34(1):91-100. doi:https:\/\/doi.org\/10.1016\/j.annonc.2022.09.161","DOI":"10.1016\/j.annonc.2022.09.161"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.007_bib0074","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncology"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.07.007_bib0075","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2022.40.16_suppl.4134","article-title":"Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)","volume":"40","author":"Schwarz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.007_bib0076","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/jhbp.1353","article-title":"Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)","volume":"30","author":"Sugiura","year":"2023","journal-title":"J Hepato-Biliary-Pancreat Sci"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.007_bib0077","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with Gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, Multicenter Phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.007_bib0078","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0079","doi-asserted-by":"crossref","first-page":"S1252","DOI":"10.1016\/j.annonc.2024.08.2304","article-title":"LBA62 Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS\/PRODIGE 44","volume":"35","author":"Lambert","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0080","doi-asserted-by":"crossref","first-page":"S1323","DOI":"10.1016\/j.annonc.2023.10.084","article-title":"LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial","volume":"34","author":"Groot Koerkamp","year":"2023","journal-title":"Ann Oncol"},{"issue":"17_suppl","key":"10.1016\/j.semradonc.2025.07.007_bib0081","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4014","article-title":"Randomized phase II\/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study","volume":"42","author":"Ikeda","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0082","doi-asserted-by":"crossref","unstructured":"Koay E.J., Zaid M., Aliru M., et al. Nab-Paclitaxel, Capecitabine, and radiation therapy after induction chemotherapy in treating patients with locally advanced and borderline resectable pancreatic cancer: phase 1 trial and imaging-based biomarker validation. Int J Radiat Oncol*Biol*Phys. ;114(3):444-453. doi:https:\/\/doi.org\/10.1016\/j.ijrobp.2022.06.089","DOI":"10.1016\/j.ijrobp.2022.06.089"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.007_bib0083","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215409","article-title":"Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies","volume":"14","author":"Yamamoto","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0084","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3389\/fonc.2019.01464","article-title":"Improving treatment response prediction for chemoradiation therapy of pancreatic cancer using a combination of delta-radiomics and the clinical biomarker CA19-9","volume":"9","author":"Nasief","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13014-023-02328-y","article-title":"Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy","volume":"18","author":"Jan","year":"2023","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.007_bib0086","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s00259-018-4251-5","article-title":"Prospective comparison of (4S)-4-(3-18F-fluoropropyl)-l-glutamate versus 18F-fluorodeoxyglucose PET\/CT for detecting metastases from pancreatic ductal adenocarcinoma: a proof-of-concept study","volume":"46","author":"Cheng","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"22","key":"10.1016\/j.semradonc.2025.07.007_bib0087","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/JCO.2010.33.8038","article-title":"Phase II trial of Cetuximab, Gemcitabine, and Oxaliplatin followed by chemoradiation with Cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4)immunostaining with pattern of disease progression","volume":"29","author":"Crane","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.07.007_bib0088","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with Losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.07.007_bib0089","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.hpb.2020.11.004","article-title":"Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer","volume":"23","author":"Zakem","year":"2021","journal-title":"HPB (Oxford)"},{"issue":"9","key":"10.1016\/j.semradonc.2025.07.007_bib0090","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX Plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.007_bib0091","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2022.6135","article-title":"Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX plus radiotherapy in patients with borderline resectable pancreatic cancer\u2014The A021501 trial","volume":"9","author":"Grossberg","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0092","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2024.03.013","article-title":"Radiation therapy Quality assurance analysis of Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated Radiation therapy for borderline resectable adenocarcinoma of the pancreas","volume":"120","author":"Tchelebi","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.007_bib0093","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/COC.0000000000000947","article-title":"Multiagent chemotherapy followed by stereotactic body radiotherapy versus conventional radiotherapy for resected pancreas cancer","volume":"45","author":"Mokhtech","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0094","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211045860","article-title":"Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma","volume":"13","author":"Bouchart","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0095","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.clon.2020.06.019","article-title":"Hypofractionated stereotactic body radiation therapy with simultaneous integrated boost and simultaneous integrated protection in pancreatic ductal adenocarcinoma","volume":"33","author":"Simoni","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"7","key":"10.1016\/j.semradonc.2025.07.007_bib0096","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncologica"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.007_bib0097","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijrobp.2020.09.010","article-title":"A phase 1 dose escalation study of neoadjuvant SBRT plus elective nodal radiation with concurrent capecitabine for resectable pancreatic cancer","volume":"109","author":"Witt","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.07.007_bib0099","article-title":"Stereotactic versus conventional radiation therapy for patients with pancreatic cancer in the modern era","volume":"6","author":"Abi Jaoude","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.07.007_bib0100","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.semradonc.2025.07.007_bib0101","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.semradonc.2025.07.007_bib0102","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of Gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.007_bib0103","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ijrobp.2021.01.055","article-title":"Investigation of relation of radiation therapy quality with toxicity and survival in LAP07 phase 3 trial for locally advanced pancreatic carcinoma","volume":"110","author":"Giraud","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.07.007_bib0104","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2025.07.007_bib0105","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO.23.01402","article-title":"Elucidating the benefit of radiation therapy in GI cancers: rethinking trial end points and patient selection","volume":"42","author":"Sanford","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.07.007_bib0106","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation Therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract Radiat Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.007_bib0107","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0108","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CEG.S341189","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer","volume":"17","author":"Neibart","year":"2024","journal-title":"Clin Exp Gastroenterol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.07.007_bib0109","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.semradonc.2025.07.007_bib0110","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S1470-2045(23)00478-3","article-title":"Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b\/2 trial","volume":"24","author":"Taniguchi","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2025.07.007_bib0111","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-013-2886-9","article-title":"Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design","volume":"20","author":"Katz","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.007_bib0112","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ijrobp.2019.07.004","article-title":"Phase 2 study of neoadjuvant treatment of sequential S-1-based concurrent chemoradiation therapy followed by systemic chemotherapy with Gemcitabine for borderline resectable pancreatic adenocarcinoma (HOPS-BR 01)","volume":"105","author":"Hayashi","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0113","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijrobp.2019.08.057","article-title":"Phase 2 trial of neoadjuvant FOLFIRINOX and intensity modulated radiation therapy concurrent with fixed-dose rate-gemcitabine in patients with borderline resectable pancreatic cancer","volume":"106","author":"Tran","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.007_bib0114","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ijrobp.2013.12.030","article-title":"Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer","volume":"88","author":"Esnaola","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.semradonc.2025.07.007_bib0115","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/s41416-021-01649-7","article-title":"A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study","volume":"126","author":"Su","year":"2022","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.007_bib0116","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.prro.2017.10.001","article-title":"Results of a prospective phase 2 clinical trial of induction gemcitabine\/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma","volume":"8","author":"Quan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0117","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): long-term outcome","volume":"155","author":"Teriaca","year":"2021","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.007_bib0118","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.semradonc.2025.07.007_bib0119","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.radonc.2020.07.052","article-title":"ESTRO ACROP guidelines for target volume definition in pancreatic cancer","volume":"154","author":"Brunner","year":"2021","journal-title":"Radiother Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.07.007_bib0121","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cam4.4527","article-title":"High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy","volume":"11","author":"Hill","year":"2022","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.007_bib0122","first-page":"1001","article-title":"The TRIANGLE operation - radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB (Oxford)","volume":"19","author":"Hackert","year":"2017","journal-title":"Nov"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.007_bib0123","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2024.10.026","article-title":"NRG Oncology international consensus contouring atlas on target volumes and dosing strategies for dose-escalated pancreatic cancer radiation therapy","volume":"121","author":"Sanford","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0124","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijrobp.2021.07.1698","article-title":"Pancreatic stereotactic body radiation therapy with or without hypofractionated elective nodal irradiation","volume":"112","author":"Miller","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.007_bib0125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000518","article-title":"Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer","volume":"42","author":"Kharofa","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.07.007_bib0126","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/MPA.0000000000001602","article-title":"Patterns of failure after neoadjuvant stereotactic body radiation therapy or fractionated chemoradiation in resectable and borderline resectable pancreatic cancer","volume":"49","author":"Barrord","year":"2020","journal-title":"Pancreas"},{"issue":"18","key":"10.1016\/j.semradonc.2025.07.007_bib0127","doi-asserted-by":"crossref","first-page":"18611","DOI":"10.1002\/cam4.6470","article-title":"Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: a prospective, open-label, phase II study","volume":"12","author":"Masui","year":"2023","journal-title":"Cancer Med"},{"issue":"13","key":"10.1016\/j.semradonc.2025.07.007_bib0128","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1245\/s10434-019-07735-8","article-title":"A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma","volume":"26","author":"Eguchi","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.radonc.2014.11.043","article-title":"Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer - a systematic review","volume":"114","author":"Bittner","year":"2015","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.007_bib0130","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.adro.2018.04.003","article-title":"Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes","volume":"3","author":"Jethwa","year":"2018","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0131","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijrobp.2015.12.362","article-title":"Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic cancer","volume":"95","author":"Shinoto","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0132","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1186\/s12885-023-11141-5","article-title":"Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial","volume":"23","author":"van Dam","year":"2023","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2025.07.007_bib0133","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41575-019-0247-2","article-title":"Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers","volume":"17","author":"Buckley","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"18","key":"10.1016\/j.semradonc.2025.07.007_bib0134","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1158\/0008-5472.CAN-05-0158","article-title":"Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras","volume":"65","author":"Brunner","year":"2005","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.007_bib0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25116249","article-title":"Triple blockade of oncogenic RAS signaling using KRAS and MEK inhibitors in combination with irradiation in pancreatic cancer","volume":"25","author":"Wang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semradonc.2025.07.007_bib0136","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/bs.acr.2023.02.004","article-title":"Targeting KRAS in pancreatic cancer: emerging therapeutic strategies","volume":"159","author":"Khan","year":"2023","journal-title":"Adv Cancer Res"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.007_bib0137","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/1535-7163.MCT-20-1103","article-title":"Radiosensitizing pancreatic cancer via effective autophagy inhibition","volume":"21","author":"Yazal","year":"2022","journal-title":"Mol Cancer Ther"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105342962500061X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105342962500061X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:54:09Z","timestamp":1762955649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105342962500061X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":137,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S105342962500061X"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.07.007","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary Advances, Evidence, and Considerations in Preoperative Therapy for Pancreatic Ductal Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}